Position in TNGX
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$29,811,000
+$13,549,052 QoQ
Shares Held
1,425,000
-65.4% QoQ
Ownership
0.985%
of shares outstanding
% of Portfolio
1.50%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2021
8 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in TNGX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Cormorant Asset Management, LP holds $1,914,987,088 across 43 Biotechnology names. TNGX ranks #19 (1.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PRAX |
Praxis Precision Medicines, Inc.
|
885,500 | $285,299,245 | |
| 2 | BBOT |
BridgeBio Oncology Therapeutics, Inc.
|
17,878,594 | $160,013,416 | |
| 3 | EYPT |
EyePoint, Inc.
|
8,265,000 | $106,535,850 | |
| 4 | EWTX |
Edgewise Therapeutics, Inc.
|
3,260,000 | $102,690,000 | |
| 5 | ERAS |
Erasca, Inc.
|
5,800,000 | $93,844,000 | |
| 6 | RAPP |
Rapport Therapeutics, Inc.
|
2,957,521 | $92,540,832 | |
| 7 | ALMS |
Alumis Inc.
|
3,949,241 | $87,001,779 | |
| 8 | ABVX |
Abivax S.A.
|
760,000 | $84,626,000 |
All Filings in TNGX
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $29,811,000 | 1,425,000 | Shares | Defined | 2026-05-15 | |
| 2023-03-31 | $16,261,948 | 4,116,949 | Shares | Defined | 2023-05-15 | |
| 2022-12-31 | $29,847,880 | 4,116,949 | Shares | Defined | 2023-02-14 | |
| 2022-09-30 | $14,903,355 | 4,116,949 | Shares | Defined | 2022-11-14 | |
| 2022-06-30 | $20,420,528 | 4,507,843 | Shares | Defined | 2022-08-15 | |
| 2022-03-31 | $37,135,822 | 4,899,185 | Shares | Defined | 2022-05-16 | |
| 2021-12-31 | $53,597,083 | 4,899,185 | Shares | Defined | 2022-02-14 | |
| 2021-09-30 | $50,416,462 | 3,899,185 | Shares | Defined | 2021-11-15 | |
| No filing history on record for this holder in this stock. | ||||||